Novel vancomycin free base-Sterosomes for combating diseases caused by Staphylococcus aureus and Methicillin-resistant Staphylococcus aureus infections (S. Aureus and MRSA)

被引:0
|
作者
Nwabuife, Joshua C. [1 ]
Hassan, Daniel [1 ]
Pant, Amit Madhaorao [1 ]
Devnarain, Nikita [1 ]
Gafar, Mohammed Ali [1 ]
Osman, Nawras [1 ]
Rambharose, Sanjeev [2 ]
Govender, Thirumala [1 ]
机构
[1] Univ KwaZulu Natal, Coll Hlth Sci, Discipline Pharmaceut Sci, ZA-4000 Durban, South Africa
[2] Stellenbosch Univ, Fac Sci, Dept Physiol Sci, Private Bag X1 Matieland, ZA-7602 Stellenbosch, South Africa
基金
新加坡国家研究基金会; 英国医学研究理事会;
关键词
Sterosomes; Novel delivery systems; Antimicrobial resistance; DRUG-DELIVERY SYSTEMS; IN-VITRO; NANOPARTICLES; ACID; NANOTECHNOLOGY; NANOSYSTEM; NANOSPHERES; PATHOGENS; EFFICACY; POLYMER;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A clarion call to save antimicrobials is the need for the evolution of novel delivery systems to combat resistance posed by Staphylococcus aureus and Methicillin-resistant Staphylococcus aureus (S. aureus and MRSA) to conventional forms. Herein, we present a novel vancomycin free base - sterosomes (VCM-FB - Sterosomes) for vancomycin free base (VCM-FB) delivery against S. aureus and MRSA. VCM-FB - Sterosomes were prepared using the thin-film hydration method and were characterised physiochemically, in silico, in vitro and in vivo. In vitro cytotoxicity on MCF-7 and HEK-293 cell lines were evaluated, with results revealing cell viability above 70% after exposure to VCM-FB - Sterosomes, indicating biosafety. VCM-FB - Sterosomes had a hydrodynamic diameter, polydispersity index and surface-charge of 114.14 +/- 0.59 nm, 0.210 +/- 0.02 and +36.3 +/- 5.42 mV, respectively, with entrapment efficiency, drug loading and VCM-FB release after 48 h of 79.61 +/- 0.59%, 90.91% w/w and 54.95 +/- 9.75% respectively. In silico studies showed a self-assembly in five nano seconds, which was stable thereafter. VCM-FB - Sterosomes were seen to be stable over 90 days and were also non-hemolytic. VCMFB - Sterosomes showed a 2-fold superior minimum inhibition efficiency (MIC) against S. aureus and MRSA, relative to bare VCM-FB, with MICs of 1.95 mu g/mL and 0.98 mu g/mL for VCM-FB and VCM-FB - Sterosomes (S. aureus), and 7.81 mu g/mL and 3.91 mu g/mL for VCM-FB and VCM-FB - Sterosomes (MRSA), respectively. A faster bacterial killing time was also recorded for VCM-FB - Sterosomes compared to bare VCM-FB. Greater MRSA membrane damage was indicated by an increase and decrease in electrical conductivity, and protein/DNA concentration, respectively. VCM-FB - Sterosomes showed superior MRSA biofilm reduction (27.22%) compared to VCM-FB (2.53%). In vivo BALB/c mice-infected skin model showed that VCM-FB - Sterosomes had significant MRSA eradication (27-fold) compared to bare VCM-FB (4-fold). These results amplify the superiority of VCM-FB - Sterosomes for S. aureus and MRSA infection treatment compared to conventional forms.
引用
收藏
页数:13
相关论文
共 50 条
  • [11] Serious Infections Caused by Methicillin-Resistant Staphylococcus aureus
    Boucher, Helen
    Miller, Loren G.
    Razonable, Raymund R.
    CLINICAL INFECTIOUS DISEASES, 2010, 51 : S183 - S197
  • [12] Methicillin-resistant Staphylococcus aureus infections
    Barry M. Farr
    Current Infectious Disease Reports, 1999, 1 (4) : 328 - 333
  • [13] Methicillin-Resistant Staphylococcus Aureus Infections
    Taylor, Abraham R.
    PRIMARY CARE, 2013, 40 (03): : 637 - +
  • [14] Methicillin-Resistant Staphylococcus aureus Infections
    Pottinger, Paul S.
    MEDICAL CLINICS OF NORTH AMERICA, 2013, 97 (04) : 601 - +
  • [15] ENDOGENOUS ENDOPHTHALMITIS CAUSED BY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA)
    Ness, Thomas
    Schneider, Christian
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2009, 29 (06): : 831 - 834
  • [16] EPIDEMIOLOGY OF NOSOCOMIAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) INFECTIONS
    Turgut, Huseyin
    Sacar, Suzan
    Sungurtekin, Hulya
    Toprak, Semra
    Asan, Ali
    Tefci, Fatma
    Tekin, Koray
    NOBEL MEDICUS, 2005, 1 (03): : 7 - 10
  • [17] Pharmacokinetics of Vancomycin in patients with Methicillin Resistant Staphylococcus aureus (MRSA) Infections
    Krishnappa, Niveditha
    Natarajan, Harivenkatesh
    Sistla, Sujatha
    Sistla, Sarath Chandra
    Vivekanandan, M.
    Girish, C.
    BRITISH JOURNAL OF PHARMACOLOGY, 2023, 180 : 351 - 355
  • [18] Lip necrosis caused by methicillin-resistant Staphylococcus aureus (MRSA)
    Khayat, Saad
    Agea Martinez, Marc
    Tousidonis Rial, Manuel
    Diez Montiel, Alberto
    Ochandiano Caicoya, Santiago
    JEADV CLINICAL PRACTICE, 2024, 3 (04): : 1253 - 1257
  • [19] METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS (MRSA)
    KEANE, CT
    IRISH MEDICAL JOURNAL, 1993, 86 (05) : 151 - &
  • [20] Methicillin-Resistant Staphylococcus Aureus (mrsa) In COPD
    Parameswaran, G. I.
    Sethi, S.
    Willet, A.
    Lesse, A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187